Literature DB >> 3007743

U50,488, a highly selective kappa opioid: anticonvulsant profile in rats.

F C Tortella, L Robles, J W Holaday.   

Abstract

Subcutaneous or i.c.v. administration of U50,488, a highly selective kappa opioid agonist, resulted in a dose-and time-dependent anticonvulsant action in rats. The anticonvulsant effect was seizure-specific; thus, U50,488 protected against supramaximal electroshock seizures but failed to raise the threshold of flurothyl-induced convulsions. The ED50 for s.c. U50,488 was 8.6 mg/kg, with a duration of action longer than 8 hr. In contrast, the ED50 for i.c.v. U50,488 was 103.8 micrograms, lasting approximately 1 hr. The anticonvulsant effect of U50,488 was partially antagonized by high (10.0 mg/kg), but not low (1.0 mg/kg), doses of s.c. administered naloxone. Results indicate that U50,488 is an efficacious, long-acting anticonvulsant against supramaximal, but not chemical threshold, seizures in rats. Furthermore, the results with naloxone suggest that this effect of U50,488 is mediated by non-mu (probably kappa) binding sites. This structurally novel nonpeptide opioid may offer new insights into the development of therapeutically effective agents in the treatment of grand mal or partial epilepsies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007743

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Opioid modulation of recurrent excitation in the hippocampal dentate gyrus.

Authors:  G W Terman; C T Drake; M L Simmons; T A Milner; C Chavkin
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

2.  Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice.

Authors:  H C Jackson; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 3.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

Review 4.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

5.  Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Ichikawa; S Togashi; T Kumanishi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

6.  Activation of κ opioid receptors increases intrinsic excitability of dentate gyrus granule cells.

Authors:  Carmel M McDermott; Laura A Schrader
Journal:  J Physiol       Date:  2011-05-23       Impact factor: 5.182

7.  Developmental and regional alteration of kappa-opioid receptors in seizure-susceptible EL mouse brain.

Authors:  T Kai; H Onishi; S Koide; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

8.  The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Authors:  Heather Cox; Daniel M Togasaki; Li Chen; J William Langston; Donato A Di Monte; Maryka Quik
Journal:  Exp Neurol       Date:  2007-02-03       Impact factor: 5.330

9.  Investigation of the involvement of opioid receptors in the action of anticonvulsants.

Authors:  H C Jackson; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Kappa opioid receptors regulate hippocampal synaptic homeostasis and epileptogenesis.

Authors:  Bridget N Queenan; Raymond L Dunn; Victor R Santos; Yang Feng; Megan N Huizenga; Robert J Hammack; Stefano Vicini; Patrick A Forcelli; Daniel T S Pak
Journal:  Epilepsia       Date:  2017-11-08       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.